YOU ARE HERE: LAT HomeCollectionsOculex Pharmaceuticals Inc

Oculex Pharmaceuticals Inc

February 1, 2000 | Dow Jones
Allergan Specialty Therapeutics Inc. said Monday that it plans to accelerate spending in its research and development plan this year, which could result in the use of nearly all funds available by mid-2001. The Irvine research firm said in a press release that the potential boost in spending is the result of more projects as well as more rapid research and development of compounds than expected. Allergan Specialty is a spinoff of eye-care pharmaceutical maker Allergan Inc.
October 15, 2003 | From Bloomberg News
Allergan Inc., maker of Botox anti-wrinkle treatments, said Tuesday that it had agreed to buy Oculex Pharmaceuticals Inc. for about $230 million in cash. Irvine-based Allergan has been shifting its focus to pharmaceutical sales after last year spinning off a business that makes eye-surgery devices. Closely held Oculex develops products to treat eye diseases such as those caused by diabetes, Allergan said. The company said it expected to complete the purchase by the end of November.
January 29, 2004 | Denise Gellene, Times Staff Writer
Allergan Inc. reported Wednesday a fourth-quarter loss due to acquisition-related expenses and other charges amid signs that the pace of Botox sales is slowing this year. The Irvine-based drug company lost $90.8 million, or 70 cents a share, in the fourth quarter, in contrast to net income of $64.4 million, or 49 cents, in the year-ago quarter. Excluding a $179-million charge related to the acquisition of Oculex Pharmaceuticals Inc. and other expenses, net income was $88.
Los Angeles Times Articles